Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04188548 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer
A Phase 1 study of Breast Cancer and Endometrial Cancer, sponsored by Eli Lilly and Company.
- Active
- Registry status
- Phase 1
- Development phase
- 500
- Enrollment target
- 20
- Study locations
NCT04188548: Active Phase 1 study of Breast Cancer and Endometrial Cancer, sponsored by Eli Lilly and Company.
NCT04188548 is a Phase 1 study of Breast Cancer and Endometrial Cancer that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 500 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (82% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04188548, a Phase 1 study of Breast Cancer and Endometrial Cancer, is active but no longer recruiting, sponsored by Eli Lilly and Company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 500 participants
- Enrollment target
- 20
- Study locations
Study Summary
The reason for this study is to see if the study drug LY3484356 alone or in combination with other anticancer therapies is safe and effective in participants with advanced or metastatic breast cancer or endometrial cancer.
Primary Outcome
Number of Participants with DLTs and DLT-Equivalent Toxicities
Conditions Studied
Interventions
- DRUG Trastuzumab
- DRUG Everolimus
- DRUG Abemaciclib
- DRUG Alpelisib
- DRUG LY3484356
Study Locations (20)
California
- Beverly Hills Cancer Center - Beverly Hills
- University of California, Irvine - Orange
- UCSF Medical Center at Mission Bay - San Francisco
New York
- Memorial Sloan Kettering Cancer Center - Commack
- Memorial Sloan Kettering Cancer Center - New York
- Wilmot Cancer Institute - Rochester
Arizona
- Banner MD Anderson Cancer Center - Gilbert
- Mayo Clinic in Arizona - Phoenix - Phoenix
Florida
- Mayo Clinic in Florida - Jacksonville
- Lake Nona DDU - Orlando
Massachusetts
- Massachusetts General Hospital - Boston
- Dana-Farber Cancer Institute - Boston
Minnesota
- Minnesota Oncology/Hematology PA - Minneapolis
- Mayo Clinic - Rochester
Arkansas
- Highlands Oncology Group - Springdale
Georgia
- Winship Cancer Center Emory University - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2019-12-10 |
| Est. Completion | 2027-12 |
| Phase | Phase 1 |
What the registry record for NCT04188548 still lists
NCT04188548 is an interventional study that assigns participants to a tested intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (82% lower).
The record links to 4 conditions, with Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which Trastuzumab is the first listed.
NCT04188548 names 20 study sites across 12 states, led by California, New York, Arizona.
Frequently Asked Questions
What is clinical trial NCT04188548 about?
NCT04188548 is a clinical study titled "A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer". The reason for this study is to see if the study drug LY3484356 alone or in combination with other anticancer therapies is safe and effective in participants with advanced or metastatic breast cancer or endometrial cancer.
What is the current status of trial NCT04188548?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 500 participants. The study started on 2019-12-10. Estimated completion is 2027-12.
What conditions does trial NCT04188548 study?
This clinical trial studies the following conditions: Breast Cancer, Endometrial Cancer, Metastatic Breast Cancer, Advanced Breast Cancer.
What interventions are being tested in trial NCT04188548?
The interventions under investigation include: Trastuzumab (DRUG), Everolimus (DRUG), Abemaciclib (DRUG), Alpelisib (DRUG), LY3484356 (DRUG).
Who is sponsoring clinical trial NCT04188548?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04188548 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04188548's enrollment target sits among peer trials
500 193rd of 1224 higher than 1,022 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI